Erin C Carruthers1, Hyon K Choi2, Eric C Sayre1, J Antonio Aviña-Zubieta3. 1. Arthritis Research Centre of Canada, Richmond, British Columbia, Canada. 2. Arthritis Research Centre of Canada, Richmond, British Columbia, Canada Division of Rheumatology, Allergy and Immunology, Department of Rheumatology, Harvard Medical School, Boston, Massachusetts, USA Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 3. Arthritis Research Centre of Canada, Richmond, British Columbia, Canada Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND/ OBJECTIVE: Patients with polymyositis (PM) and dermatomyositis (DM) may have an increased risk of venous thromboembolism (VTE); however, no general population data are available to date. The purpose of this study was to estimate the future risk and time trends of new VTE (deep venous thrombosis (DVT) or pulmonary embolism (PE)) in individuals with incident PM/DM at the general population level. METHODS: We assembled a retrospective cohort of all patients with incident PM/DM in British Columbia and a corresponding comparison cohort of up to 10 age-matched, sex-matched and entry-time-matched individuals from the general population. We calculated incidence rate ratios (IRR) for VTE, DVT and PE and stratified by disease duration. We calculated HRs adjusting for relevant confounders. RESULTS: Among 752 cases with inflammatory myopathies, 443 had PM (58% female, mean age 60 years) and 355 had DM (65% female, mean age 56 years); 46 subjects developed both diseases. The corresponding IRRs (95% CI) for VTE, DVT and PE in PM were 8.14 (4.62 to 13.99), 6.16 (2.50 to 13.92) and 9.42 (4.59 to 18.70), respectively. Overall, the highest IRRs for VTE, DVT and PE were observed in the first year after PM diagnosis (25.25, 9.19 and 38.74, respectively). Fully adjusted HRs for VTE, DVT and PE remained statistically significant (7.0 (3.34 to 14.64), 6.16 (2.07 to 18.35), 7.23 (2.86 to 18.29), respectively). Similar trends were seen in DM. CONCLUSIONS: These findings provide the first general population-based evidence that patients with PM/DM have an increased risk of VTE. Increased vigilance of this serious but preventable complication is recommended. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND/ OBJECTIVE:Patients with polymyositis (PM) and dermatomyositis (DM) may have an increased risk of venous thromboembolism (VTE); however, no general population data are available to date. The purpose of this study was to estimate the future risk and time trends of new VTE (deep venous thrombosis (DVT) or pulmonary embolism (PE)) in individuals with incident PM/DM at the general population level. METHODS: We assembled a retrospective cohort of all patients with incident PM/DM in British Columbia and a corresponding comparison cohort of up to 10 age-matched, sex-matched and entry-time-matched individuals from the general population. We calculated incidence rate ratios (IRR) for VTE, DVT and PE and stratified by disease duration. We calculated HRs adjusting for relevant confounders. RESULTS: Among 752 cases with inflammatory myopathies, 443 had PM (58% female, mean age 60 years) and 355 had DM (65% female, mean age 56 years); 46 subjects developed both diseases. The corresponding IRRs (95% CI) for VTE, DVT and PE in PM were 8.14 (4.62 to 13.99), 6.16 (2.50 to 13.92) and 9.42 (4.59 to 18.70), respectively. Overall, the highest IRRs for VTE, DVT and PE were observed in the first year after PM diagnosis (25.25, 9.19 and 38.74, respectively). Fully adjusted HRs for VTE, DVT and PE remained statistically significant (7.0 (3.34 to 14.64), 6.16 (2.07 to 18.35), 7.23 (2.86 to 18.29), respectively). Similar trends were seen in DM. CONCLUSIONS: These findings provide the first general population-based evidence that patients with PM/DM have an increased risk of VTE. Increased vigilance of this serious but preventable complication is recommended. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Mary A De Vera; Hyon Choi; Michal Abrahamowicz; Jacek Kopec; Maria Victoria Goycochea-Robles; Diane Lacaille Journal: Ann Rheum Dis Date: 2011-03-06 Impact factor: 19.103
Authors: Vincent J Willey; Michael F Bullano; Ole Hauch; Matthew Reynolds; Gail Wygant; Lauren Hoffman; George Mayzell; Alex C Spyropoulos Journal: Clin Ther Date: 2004-07 Impact factor: 3.393
Authors: Ada Man; Yanyan Zhu; Yuqing Zhang; Maureen Dubreuil; Young Hee Rho; Christine Peloquin; Robert W Simms; Hyon K Choi Journal: Ann Rheum Dis Date: 2012-08-17 Impact factor: 19.103
Authors: Lingyi Li; Na Lu; Ana Michelle Avina-Galindo; Yufei Zheng; Diane Lacaille; John M Esdaile; Hyon K Choi; J Antonio Aviña-Zubieta Journal: Rheumatology (Oxford) Date: 2021-01-05 Impact factor: 7.580
Authors: Sara R Schoenfeld; Hyon K Choi; Eric C Sayre; J Antonio Aviña-Zubieta Journal: Arthritis Care Res (Hoboken) Date: 2016-02 Impact factor: 4.794
Authors: Michał Nowak; Katarzyna Królak-Nowak; Aleksandra Sobolewska-Włodarczyk; Jakub Fichna; Marcin Włodarczyk Journal: Vasc Health Risk Manag Date: 2016-06-03